Revuforj® (revumenib)
for Leukemia

Revuforj (revumenib) is a menin inhibitor approved to treat acute leukemia with KMT2A gene translocation in adults and children (≥1 year old) whose leukemia has returned or resisted prior treatments. It works by blocking interactions between menin and KMT2A fusion proteins, preventing menin-driven cancer growth.

Heart
Other top medicines used to treat Leukemia